MetaCap

Voyager Therapeutics Inc. Company Profile

NASDAQ: VYGRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.53-0.08 (-4.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Voyager Therapeutics at a glance

Voyager Therapeutics Inc. (NASDAQ: VYGR) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Lexington, MA. Voyager Therapeutics is led by Dr. Alfred W. Sandrock Jr., M.D., Ph.D. and employs about 141 people. The company's shares have traded publicly since 2015.

At a market capitalization of $95.2 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001640266, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Voyager Therapeutics do?

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Voyager Therapeutics Inc.
Ticker
NASDAQ: VYGR
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Employees
141
Headquarters
75 Hayden Avenue, Lexington, MA, United States
Phone
857 259 5340
IPO year
2015
Market cap
$95.21M
SEC CIK
0001640266
Latest annual report
10-K · Mar 9, 2026

Companies similar to Voyager Therapeutics

VYGR peer companies
CompanyPrice% ChgMarket capCompare
OTLKOutlook Therapeutics Inc.0.39-2.74%$94.94Mvs VYGR
IPHAInnate Pharma S.A. ADS0.8634-8.14%$96.44Mvs VYGR
MOLNMolecular Partners AG ADR2.53-5.25%$96.80Mvs VYGR
LENZLENZ Therapeutics Inc.2.97-11.23%$93.16Mvs VYGR
ZURAZura Bio Limited Class A0.9305-2.30%$89.63Mvs VYGR
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs VYGR
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs VYGR
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs VYGR

Related